Improving adherence to essential medication for asthma: Feasibility study for the ‘Perceptions and Practicalities Intervention’ (PAPI)

North ThamesRespiratory
Start Date: 1 Apr 2015

Project summary

5.4 million people in the UK are currently receiving treatment for asthma costing the NHS approximately £1 billion per year. It is estimated that 75% of hospital admissions for asthma are preventable, as are 90% of the 1,000 UK annual deaths from asthma, with more effective self-management, particularly optimal adherence to appropriately prescribed medication.

Members of the project team have developed a suite of valid and reliable, ‘low impact’ assessment tools to identify non-adherence and tailor support to overcome perceptual and practical barriers to adherence. These are incorporated in a Perceptions and Practicalities Intervention (PAPI), which is designed to improve adherence to asthma medication by supporting patients and practitioners to identify and address the salient barriers and facilitators to adherence for individual patients. PAPI can be delivered via a range of vehicles including on-line programmes and mobile phone Apps, however, the approach has not been formally tested.

This project, will be conducted in collaboration with the Asthma UK Centre for Applied Research (AUK CAR) and our Child and Adolescent Theme partners. We will finalise and manualise the PAPI; evaluate its feasibility and acceptability to patients and practitioners, and the costs of intervention. In the longer term we will apply for external funding to undertake a randomised controlled trial of the effectiveness and cost effectiveness of the adherence intervention; and adapt the intervention for application to children with asthma.

The results of this project will benefit patients by: promoting informed choice about prescribed medicines and helping them to get the best form essential treatment so improving quality of life, reducing time off work and away from school and even, in some cases, helping to prevent avoidable deaths from asthma.

Prof Rob Horne